Effect of Rivaroxaban on thrombin generation in vivo. A study in obese patients

No abstract is available for this paper.

• Publication year

  2018

• Venue

  International Journal of Laboratory Hematology

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ijlh.12767PMID 29239121
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery

  2017cited by this paper
• Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial

  2016cited by this paper
• Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.

  2015cited by this paper
• Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.

  2012cited by this paper
• Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.

  2011cited by this paper
• The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation

  2010cited by this paper
• Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor

  2010cited by this paper
• Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

  2008cited by this paper
• Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity 1

  2007cited by this paper
• In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban

  2007cited by this paper
• In vitro and in vivo studies of the novel antithrombotic agent BAY 59‐7939—an oral, direct Factor Xa inhibitor

  2005cited by this paper
• Calibrated Automated Thrombin Generation Measurement in Clotting Plasma

  2003cited by this paper

• Effect of direct oral anticoagulants in cirrhosis: an in vitro study.

  2025cites this paper
• Fibrinography and thrombography (thrombodynamics-4D) in atrial fibrillation assessment of direct oral anticoagulants in geriatrics patients aged 80 years and older receiving direct oral anticoagulant therapy

  2025cites this paper
• Assessment of rivaroxaban as venous thromboembolism prophylaxis after gastric bypass surgery

  2024cites this paper
• Direct oral anticoagulants in cirrhosis: Rationale and current evidence

  2024cites this paper
• Intrinsic coagulant potential modulates anticoagulant efficacy of rivaroxaban.

  2024cites this paper
• Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery

  2023cites this paper
• Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland.

  2023cites this paper
• Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases

  2022cites this paper
• Assessment of DOAC in GEriatrics ( Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients

  2022cites this paper
• Thrombosis and Haemostasis Assessment of DOAC in GEriatrics (ADAGE study): rivaroxaban/apixaban concentrations and thrombin generation profiles in NVAF very elderly patients academic prospective exploratory multicenter study

  2022cites this paper
• Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements

  2021cites this paper
• Thrombotic storm under DOAC treatment in a patient with homozygous antithrombin Budapest III mutation.

  2021cites this paper
• Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants

  2020cites this paper
• Does One Dose Really Fit All? On the Monitoring of Direct Oral Anticoagulants: A Review of the Literature

  2020cites this paper
• Use of direct‐acting oral anticoagulants in solid organ transplantation: A systematic review

  2020cites this paper
• Thrombin generation in a woman with heterozygous factor V Leiden and combined oral contraceptives: A case report

  2020cites this paper
• Hyper-coagulability in obese patients accurately identified by combinations of global coagulation assay parameters.

  2020cites this paper
• Use of Direct Oral Anticoagulants in Morbidly Obese Patients

  2019cites this paper
• Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability

  2019cites this paper
• Reply to: The effect of bariatric surgery on direct-acting oral anticoagulant drug levels.

  2018cites this paper